SCHEMBL1764633

SCHEMBL1764633

CN(C)C(=O)C(N)Cc1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALPI P09923 1/20 0.63
PKM P14618 1/20 0.63
PTGS1 P23219 1/20 0.63
XIAP P98170 1/20 0.63
SLC7A5 Q01650 1/20 0.63
SLC15A1 P46059 1/20 0.54
MMP9 P14780 1/20 0.53
MMP8 P22894 1/20 0.53
MMP14 P50281 1/20 0.53
LTA4H P09960 1/20 0.51
HPGD P15428 1/20 0.51
SLC1A3 P43003 2/20 0.50
SLC1A2 P43004 2/20 0.50
SLC1A1 P43005 2/20 0.50
HDAC8 Q9BY41 2/20 0.49
SLC6A2 P23975 2/20 0.48
TAAR1 Q96RJ0 2/20 0.48
MAOA P21397 1/20 0.48
SLC6A4 P31645 1/20 0.48
SLC6A3 Q01959 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL836806 1.00 ALPI (0.63) ALPIPKMPTGS1XIAPSLC7A5
SCHEMBL30959049 1.00 ALPI (0.63) ALPIPKMPTGS1XIAPSLC7A5
SCHEMBL26954884 1.00 ALPI (0.63) ALPIPKMPTGS1XIAPSLC7A5
Hydrochloric Acid SCHEMBL2106554 0.98 ALPI (0.61) ALPIPKMPTGS1XIAPSLC7A5
Hydrochloric Acid SCHEMBL6164895 0.98 ALPI (0.61) ALPIPKMPTGS1XIAPSLC7A5
Hydrochloric Acid SCHEMBL2106555 0.98 ALPI (0.61) ALPIPKMPTGS1XIAPSLC7A5
Bromide SCHEMBL10797451 0.98 ALPI (0.61) ALPIPKMPTGS1XIAPSLC7A5
SCHEMBL27322134 0.93 SLC7A5 (0.56) ALPIPKMPTGS1XIAPSLC7A5
Trifluoroacetic Acid SCHEMBL2494748 0.92 ALPI (0.54) ALPIPKMPTGS1XIAPSLC7A5
SCHEMBL2807468 0.90 MC4R (0.55) ALPIPKMPTGS1XIAPSLC7A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1725238-A4 M 3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS GLAXO GROUP LTD (GB) 2009-04-01 EP claimed
EP-1725238-A2 M 3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS GLAXO GROUP LIMITED (GB) 2006-11-29 EP claimed
WO-2005094251-A2 M3MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS GLAXO GROUP LIMITED (GB) 2005-10-13 WO claimed
EP-4509517-A1 PEPTIDE SYNTHESIS METHOD FOR SUPPRESSING DEFECT CAUSED BY DIKETOPIPERAZINE FORMATION CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-02-19 EP disclosed
US-20230391818-A1 PEPTIDE SYNTHESIS METHOD FOR SUPPRESSING DEFECT CAUSED BY DIKETOPIPERAZINE FORMATION CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-12-07 US disclosed
EP-4242219-A1 PEPTIDE SYNTHESIS METHOD FOR SUPPRESSING DEFECT CAUSED BY DIKETOPIPERAZINE FORMATION CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-09-13 EP disclosed
US-20220403297-A1 PRO-BENEFIT-AGENT COMPOUNDS WITH CARBON/NITROGEN BONDS THE PROCTER & GAMBLE COMPANY 2022-12-22 US disclosed
US-10968183-B2 Small molecule FIEL1 inhibitor in inflammatory and fibrotic lung injury University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2021-04-06 US disclosed
US-10344003-B2 Small molecule FIEL1 inhibitor in inflammatory and fibrotic lung injury University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2019-07-09 US disclosed
US-20180141916-A1 NOVEL SMALL MOLECULE FIEL1 INHIBITOR IN INFLAMMATORY AND FIBROTIC LUNG INJURY UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2018-05-24 US disclosed
WO-2016172325-A1 NOVEL SMALL MOLECULE FIEL1 INHIBITOR IN INFLAMMATORY AND FIBROTIC LUNG INJURY UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2016-10-27 WO disclosed
EP-1134213-A2 Process for the preparation of substituted N-(indole-2-carbonyl)- glycinamides PFIZER INC. (US) 2001-09-19 EP disclosed
US-6277877-B1 GLYCOGEN PHOSPHORYLASE INHIBITOR; ANTIDIABETIC AGENTS PFIZER, INC. 2001-08-21 US disclosed
US-6107329-A HYPOTENSIVE AGENTS; CARDIOVASCULAR DISORDERS PFIZER, INC. (US) 2000-08-22 US disclosed
EP-0832065-A1 SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS PFIZER INC. (US) 1998-04-01 EP disclosed
WO-1996039384-A1 SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS PFIZER, INC. (US) 1996-12-12 WO disclosed
EP-0495013-B1 HEXAPEPTIDES WITH SULPHATE ESTER GROUPS FISONS CORP (US) 1995-03-08 EP disclosed
EP-0226217-B1 Peptides with sulfate ester group FISONS CORP (US) 1994-01-26 EP disclosed
EP-0495013-A1 HEXAPEPTIDES WITH SULPHATE ESTER GROUPS. FISONS CORP (US) 1992-07-22 EP disclosed
WO-1991008225-A1 HEXAPEPTIDES WITH SULPHATE ESTER GROUPS FISONS CORPORATION (US) 1991-06-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10344003-B2 Small molecule FIEL1 inhibitor in inflammatory and fibrotic lung injury FIP1L1, TRIM28, TFPI2 ALPI 4655/4885PKM 4293/4885PTGS1 85/4885
US-20180141916-A1 NOVEL SMALL MOLECULE FIEL1 INHIBITOR IN INFLAMMATORY AND FIBROTIC LUNG INJURY FIP1L1, TRIM28, TFPI2 ALPI 4674/4885PKM 4280/4885PTGS1 105/4885
US-20230391818-A1 PEPTIDE SYNTHESIS METHOD FOR SUPPRESSING DEFECT CAUSED BY DIKETOPIPERAZINE FORMATION VIP, DNPEP, NPPA ALPI 4260/4885PKM 511/4885PTGS1 3125/4885
US-10968183-B2 Small molecule FIEL1 inhibitor in inflammatory and fibrotic lung injury FIP1L1, TRIM28, TFPI2 ALPI 4655/4885PKM 4293/4885PTGS1 85/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.